Protara Therapeutics, Inc. Increase (Decrease) in Other Operating Liabilities
Protara Therapeutics, Inc. (TARA) reported Increase (Decrease) in Other Operating Liabilities of -$731.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2024-11-12
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2024-09-30 was -$248.00K.
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2024-06-30 was -$243.00K.
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2024-03-31 was -$240.00K.
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2023-12-31 was -$235.00K.
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was -$917.00K.
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2022 was -$1.33M.
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2021 was -$1.01M.
- Protara Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2020 was -$66.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$491.00K derived: sum of 2 quarters · filed 2024-11-12 | -$731.00K 10-Q · filed 2024-11-12 | -$966.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | -$243.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$483.00K 10-Q · filed 2024-08-06 | -$718.00K derived: sum of 3 quarters · filed 2024-08-06 | -$737.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | -$240.00K 10-Q · filed 2024-05-02 | -$475.00K derived: sum of 2 quarters · filed 2024-05-02 | -$494.00K derived: sum of 3 quarters · filed 2024-11-12 | -$825.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | -$235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$254.00K derived: sum of 2 quarters · filed 2024-11-12 | -$585.00K derived: sum of 3 quarters · filed 2024-11-12 | -$917.00K 10-K · filed 2024-03-13 |
| 2023-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$350.00K derived: sum of 2 quarters · filed 2024-11-12 | -$682.00K 10-Q · filed 2024-11-12 | -$1.01M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$663.00K 10-Q · filed 2024-08-06 | -$995.00K derived: sum of 3 quarters · filed 2024-08-06 | -$1.33M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$332.00K 10-Q · filed 2024-05-02 | -$664.00K derived: sum of 2 quarters · filed 2024-05-02 | -$996.00K derived: sum of 3 quarters · filed 2024-05-02 | -$1.33M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$664.00K derived: sum of 2 quarters · filed 2024-03-13 | -$995.00K derived: sum of 3 quarters · filed 2024-03-13 | -$1.33M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$332.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$663.00K derived: sum of 2 quarters · filed 2023-11-03 | -$995.00K 10-Q · filed 2023-11-03 | -$1.30M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$663.00K 10-Q · filed 2023-08-03 | -$965.00K derived: sum of 3 quarters · filed 2023-08-03 | -$1.24M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$332.00K 10-Q · filed 2023-05-04 | -$634.00K derived: sum of 2 quarters · filed 2023-05-04 | -$911.00K derived: sum of 3 quarters · filed 2023-05-04 | -$1.29M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$579.00K derived: sum of 2 quarters · filed 2023-03-08 | -$957.00K derived: sum of 3 quarters · filed 2023-03-08 | -$1.01M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$277.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$655.00K derived: sum of 2 quarters · filed 2022-11-03 | -$707.00K 10-Q · filed 2022-11-03 | -$737.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$378.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$430.00K 10-Q · filed 2022-08-09 | -$460.00K derived: sum of 3 quarters · filed 2022-08-09 | -$481.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$52.00K 10-Q · filed 2022-05-05 | -$82.00K derived: sum of 2 quarters · filed 2022-05-05 | -$103.00K derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$51.00K derived: sum of 2 quarters · filed 2022-03-09 | -$66.00K 10-K · filed 2022-03-09 | |
| 2020-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$36.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$15.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |